MC
VTYX

Moors & Cabot’s Ventyx Biosciences VTYX Stock Holding History

Moors & Cabot’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,600
Closed -$229K – 893
2023
Q3 		$229K Hold
6,600
– – 0.02% 692
2023
Q2 		$216K Hold
6,600
– – 0.01% 723
2023
Q1 		$221K Hold
6,600
– – 0.02% 721
2022
Q4 		$216K Buy
6,600
+600
+10% +$17.8K 0.02% 709
2022
Q3 		$209K Buy
+6,000
New +$133K 0.02% 693

Other funds holding VTYX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Moors & Cabot's VTYX Position: Q4 2023 in Review

Moors & Cabot sold out of Ventyx Biosciences (VTYX) in Q4 2023, closing a stake of 6,600 shares — an estimated $229K sold.

Moors & Cabot first reported a position in VTYX in Q3 2022 and held it in 5 quarters. The position peaked at $229K in Q3 2023. 121 funds tracked by Wall St. Rank hold VTYX as of Q4 2023.

  • Moors & Cabot reported no remaining Ventyx Biosciences position as of Q4 2023 after selling out during the quarter.
  • Moors & Cabot sold 6,600 Ventyx Biosciences shares in Q4 2023, an estimated $229K.
  • Moors & Cabot first reported a position in Ventyx Biosciences in Q3 2022 and held it in 5 quarters.
  • Moors & Cabot's Ventyx Biosciences position peaked at $229K in Q3 2023.
  • 121 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2023.

Based on Moors & Cabot's 13F filing for Q4 2023, filed 14 Feb 2024.